Efficacy of Taletrectinib (AB-106/DS-6051b) in ROS1+ NSCLC: An Updated Pooled Analysis of U.S. and Japan Phase 1 Studies

Efficacy of Taletrectinib (AB-106/DS-6051b) in ROS1+ NSCLC: An Updated Pooled Analysis of U.S. and Japan Phase 1 Studies

Introduction: Taletrectinib (AB-106/DS-6051b) is an oral, potent selective ROS1 and pan-NTRK tyrosine kinase inhibitor (TKI). Preclinically, taletrectinib has activity against ROS1 G2032R solvent-front mutation. Methods: Patients with ROS1+ NSCLC enrolled into two phase 1 studies conducted in United...

Full description

Bibliographic Details
Main Authors: Sai-Hong Ignatius Ou, MD, PhD, Yutaka Fujiwara, MD, PhD, Alice T. Shaw, MD, PhD, Noboru Yamamoto, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Frank Fan, MD, Yuki Hao, MSc, Yanfei Gao, MSc, Pasi A. Jänne, MD, Takashi Seto, MD
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:JTO Clinical and Research Reports
Subjects:
Taletrectinib
DS-6051b
AB-106
ROS1+ NSCLC
Crizotinib resistance
Pooled analysis
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364320301545

Internet

http://www.sciencedirect.com/science/article/pii/S2666364320301545

Similar Items